Satish Frank Kishore Lubeek

Satish Frank Kishore Lubeek

Auto-generated profile, based on publicly available information

Satish Frank Kishore Lubeek

Department of Dermatology Radboud University Medical Center Nijmegen the Netherlands

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
EZellen zwijnenburg
ellen zwijnenburg
SLSatish F.K. Lubeek
Satish F.K. Lubeek
JWJohanna E.M. Werner
Johanna E.M. Werner
AAAvital L. Amir
Avital L. Amir
WWWillem L.J. Weijs
Willem L.J. Weijs
Johannes KaandersJohannes Kaanders
Johannes Kaanders
Merkel cell carcinoma (MCC) is a rare neuroendocrine tumor of the skin mainly seen in the elderly. Its incidence is rising due to ageing of the population, increased sun exposure, and the use of immunosuppressive medication. Additionally, with the availability of specific immunohistochemical markers, MCC is easier to recognize. Typically, these tumors are rapidly progressive and behave aggressively, emphasizing the need for early detection and prompt diagnostic work-up and start of treatment. In this review, the tumor biology and immunology, current diagnostic and treatment modalities, as well as new and combined therapies for MCC, are discussed. MCC is a very immunogenic tumor which offers good prospects for immunotherapy. Given its rarity, the aggressiveness, and the frail patient population it concerns, MCC should be managed in close collaboration with an experienced multidisciplinary team.

6 July 2020 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
WWW. Woliner–Van der Weg
W. Woliner–Van der Weg
MPM. Peppelman
M. Peppelman
YEY.S. Elshot
Y.S. Elshot
MVM.B. Visch
M.B. Visch
MCM.B. Crijns
M.B. Crijns
SLS.F.K. Lubeek
S.F.K. Lubeek
Background Reflectance confocal microscopy (RCM) is a non‐invasive method for skin assessment, allowing entire lesion evaluation up to the papillary dermis. Therefore, RCM is a potentially attractive alternative to punch biopsy in basal cell carcinoma (BCC). Objectives and design This randomized controlled trial aimed to investigate RCM as alternative to punch biopsy in a real‐world clinical setting. Primary objective was to determine the diagnostic accuracy of RCM compared to punch biopsy in diagnosing and subtyping BCC. Secondary objectives were to study related patient satisfaction and preferences. Methods Patients with a clinically suspected primary BCC were randomized between RCM and biopsy. Conventional surgical excision or follow‐up were used as reference. Sensitivity and specificity for BCC diagnosis and subtyping were calculated for both methods. BCC subtype was stratified based on clinical relevance: aggressive (infiltrative/micronodular) versus non‐aggressive (superficial/nodular) histopathological subtype and superficial versus non‐superficial BCC. Data on patient satisfaction and preferences werecollected using a questionnaire and a contingent valuation method. Results Sensitivity for BCC diagnosis was high and similar for both methods (RCM 99.0% versus biopsy 99.0%, p=1.00). Specificity for BCC diagnosis was lower with RCM (59.1% versus 100.0%, p<0.001). Sensitivity for aggressive BCC subtypeswas lower for RCM (33.3% versus 77.3%, p=0.003). Sensitivity for non‐superficial BCC was not significantly different (RCM 88.9% versus biopsy 91.0%, p=0.724). Patient satisfaction and preferences were good and highly comparable for both methods. Conclusions Biopsy outperforms RCM in diagnosing and subtyping clinically suspected primary BCC. This outcome does not support routine clinical implementation of RCM, as a replacement of punch biopsies in this patient group.

14 May 2020 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
EME. Marra
E. Marra
MRM.C.J. van Rijsingen
M.C.J. van Rijsingen
JAJ.A.C. Alkemade
J.A.C. Alkemade
JGJ.M.M. Groenewoud
J.M.M. Groenewoud
KHK.F. Hueskes
K.F. Hueskes
SLS.F.K. Lubeek
S.F.K. Lubeek
Background The rising incidence rates of skin cancer (SC) lead to an enormous burden on healthcare systems. General practitioners (GPs) might play an important part in SC care, but research showed poor clinical recognition of SC, leading to a high rate of potentially unnecessary referrals. Objectives The aim of this study was to evaluate if a dermato‐oncologic training program (DOTP) for GPs improved their diagnostic skills and quality of referrals. Methods 83 (42,8%) out of 194 GPs in the Nijmegen area followed a DOTP on SC. Referrals from both a trained cohort (TC) and two cohorts of untrained GPs (untrained present cohort (UPC) and untrained historical cohort (UHC)) were included. Data on diagnostic skills, quality of referrals and the amount of potentially unnecessary referrals, were evaluated. Results A total number of 1662 referrals were analysed. The referral diagnosis was more often correct in the TC (70,3%) compared to the UPC (56,2%; P<.001) and the UHC (51,6%; P<.001). Furthermore, the TC also had a better lesion description, more often mentioned a diagnosis in their referral letters and more often performed diagnostics before referral. In addition, less potentially unnecessary referrals were identified in the TC compared to the UPC (65,2% vs 77,1%; P<.001) and the UHC (76,5%; P<.001). Conclusion GPs who followed a DOTP had better diagnostic skills and quality of referrals than untrained GPs, leading to less potentially unnecessary referrals. This might enhance a more efficient use of the limited capacity in secondary dermatologic care and consequently leads to lower healthcare costs.

13 September 2016 in British Journal of Dermatology
Verified
Journal Article
Closed access
SLS.F.K. Lubeek
S.F.K. Lubeek
RBR.J. Borgonjen
R.J. Borgonjen
LVL.J. van Vugt
L.J. van Vugt
MRM.G. Olde Rikkert
M.G. Olde Rikkert
PKP.C.M. van de Kerkhof
P.C.M. van de Kerkhof
MGM.J.P. Gerritsen
M.J.P. Gerritsen

21 July 2022 in Drugs & Aging
Verified
Journal Article
Open access
PDF file
EHElke ter Haar
Elke ter Haar
STS. E. Thomas
S. E. Thomas
JRJ. M. P. A. van Den Reek
J. M. P. A. van Den Reek
MOM. E. Otero
M. E. Otero
MNM. D. Njoo
M. D. Njoo
EJE. M. G. J. de Jong
E. M. G. J. de Jong
Background Psoriasis is a common inflammatory disease in any age group, but also in older patients (≥ 65 years of age). Since older patients are often excluded from clinical trials, limited data specifically on this growing population are available, e.g. regarding the safety and performance of biological treatment. Aims We aimed to give insight into this specific population by comparing the drug survival and safety of biologics in older patients with that in younger patients. Methods In this real-world observational study, data from 3 academic and 15 non-academic centers in The Netherlands were extracted from the prospective BioCAPTURE registry. Biologics included in this study were tumor necrosis factor (TNF)-α, interleukin (IL)-17, IL-12/23, and IL-23 inhibitors. Patients were divided into two age groups: ≥ 65 years and < 65 years. The Charlson Comorbidity Index (CCI) was used to measure comorbid disease status, and all adverse events (AEs) that led to treatment discontinuation were classified according to the Medical Dictionary for Regulatory Activities (MedDRA) classification. All AEs that led to treatment discontinuation were studied to check whether they could be classified as serious AEs (SAEs). Kaplan–Meier survival curves for overall 5-year drug survival and split according to reasons of discontinuation (ineffectiveness or AEs) were constructed. Cox regression models were used to correct for possible confounders and to investigate associations with drug survival in both age groups separately. Psoriasis Area and Severity Index (PASI) scores during the first 2 years of treatment and at the time of treatment discontinuation were assessed and compared between age groups. Results A total of 890 patients were included, of whom 102 (11.4%) were aged ≥ 65 years. Body mass index, sex, and distribution of biologic classes (e.g. TNFα, IL12/23) were not significantly different between the two age groups. A significantly higher CCI score was found in older patients, indicative of more comorbidity (p < 0.001). The 5-year ineffectiveness-related drug survival was lower for older patients (44.5% vs. 60.5%; p = 0.006), and the 5-year overall (≥ 65 years: 32.4% vs. < 65 years: 42.1%; p = 0.144) and AE-related (≥ 65 years: 82.1% vs. < 65 years: 79.5%; p = 0.913) drug survival was comparable between age groups. Of all AEs (n = 155) that led to discontinuation, 16 (10.3%) were reported as SAEs but these only occurred in younger patients. After correcting for confounders, the same trends were observed in the drug survival outcomes. Linear regression analyses on PASI scores showed no statistical differences at 6, 12, 18, and 24 months of treatment between age groups. Conclusions This study in a substantial, well-defined, prospective cohort provides further support that the use of biologics in older patients seems well-tolerated and effective. Biologic discontinuation due to AEs did not occur more frequently in older patients. Older patients discontinued biologic treatment more often due to ineffectiveness, although no clear difference in PASI scores was observed. More real-world studies on physician- and patient-related factors in older patients are warranted.

13 May 2020 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
PDF file
MWM.E.C. van Winden
M.E.C. van Winden
SGSimone Garcovich
Simone Garcovich
KPKetty Peris
Ketty Peris
GCGiuseppe Ferdinando Colloca
Giuseppe Ferdinando Colloca
EJE.M.G.J. de Jong
E.M.G.J. de Jong
SLS.F.K. Lubeek
S.F.K. Lubeek
Background: Appropriate management and prevention of both under‐ and overtreatment in older skin cancer patients can be challenging. It could be helpful to incorporate frailty screening in dermato‐oncology care, since frailty is associated with adverse health outcomes.Objectives: This study aimed to identify and prioritize the requirements a frailty screening tool (FST) should fulfil in dermato‐oncology practice and to select the best existing FST(s) for this purpose.Methods: A modified two‐round Delphi procedure was performed among 50 Italian and Dutch specialists and patients to review and prioritize a list of potential FST requirements, using a 5‐point Likert scale. Consensus was defined as a mean score of ≥4.0. A systematic literature search was performed to identify existing multidomain FSTs, which were then assessed on the requirements resulting from the modified Delphi procedure.Results: Consensus was achieved on evaluation of comorbidities (4.3 ± 0.7), polypharmacy (4.0 ± 0.9) and cognition (4.1 ± 0.8). The FST should have appropriate measurement properties (4.0 ± 1.0), be quickly executed (4.2 ± 0.7), clinically relevant (4.3 ± 0.7), and both easily understandable (4.1 ± 1.2) and interpretable (4.3 ± 0.7). Of the 26 identified FSTs, four evaluated the content‐related domains: the Geriatric‐8 (G8), the modified Geriatric‐8 (mG8), the Groningen Frailty Indicator (GFI) and the Senior Adult Oncology Program 2 (SAOP2) screening tool. Of these, the G8 was the most extensively studied FST, with the best psychometric properties and execution within 5 min.Conclusions: The G8 appears the most suitable FST for assessing frailty in older adults with skin cancer, although clinical studies assessing its use in a dermato‐oncology population are needed to further assess whether or not frailty in this particular patient group is associated with relevant outcomes (e.g. complications and mortality), as seen in previous studies in other medical fields.